Polymorphism at codon 31 of CDKN1A (p21) as a predictive factor for bevacizumab therapy in glioblastoma multiforme. Cheng WY, Shen CC, Liang YJ, Chiao MT, et al. BMC Cancer 2023;23:886.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Cheng WY, Shen CC, Liang YJ, Chiao MT, et al. Polymorphism at codon 31 of CDKN1A (p21) as a predictive factor for bevacizumab therapy in glioblastoma multiforme. BMC Cancer 2023;23:886.
PMID: 37730565